ORAMED PHARMACEUTICALS INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.0M | — | $1.3M | $2.7M | — |
| Gross profit | $13,000 | — | — | — | — |
| Operating income | -$15.1M | -$12.8M | -$15.8M | -$40.6M | — |
| Cost of revenue | $2.0M | — | — | — | — |
| Cash from operations | -$9.1M | -$8.4M | -$10.3M | -$27.9M | — |
| Capital expenditure | $9,000 | $18,000 | $254,000 | $496,000 | — |
| Free cash flow | -$9.2M | -$8.4M | -$10.5M | -$28.4M | — |
| Share repurchases | $4.7M | $2.5M | — | — | — |
| Total assets | $230.9M | $155.3M | $220.6M | $161.6M | $177.8M |
Shares outstanding 40.9M · Free float 32.1%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.